Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Research Area > Oncology Research > Esophageal Cancer

Esophageal Cancer Research Reagents

Esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer death worldwide. Esophageal squamous cell carcinoma (ESCC) predominates in East Asia, while esophageal adenocarcinoma (EAC) is increasing in Western countries, linked to Barrett’s esophagus. Immune checkpoint inhibitors (nivolumab, pembrolizumab) have transformed treatment, with PD-L1 TPS and CPS guiding immunotherapy selection across both subtypes.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Esophageal Cancer Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in esophageal cancer. ESCC vs. EAC molecular profiles, PD-1/PD-L1 immune checkpoint, HER2 amplification, and TP53 alterations. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key esophageal cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

PD-L1 (CD274) — PD-L1 expression is the primary biomarker for immunotherapy in esophageal cancer, with TPS ≥1% (ESCC) and CPS ≥10 (EAC) guiding treatment decisions. Anti-PD-L1 antibodies support expression scoring, tumor-immune cell co-analysis, and checkpoint combination therapy research across both histological subtypes.
→ Browse PD-L1 antibodies & proteins

HER2 (ERBB2) — HER2 overexpression occurs in 15–30% of EAC/GEJ adenocarcinoma. Anti-HER2 antibodies enable IHC scoring with gastric/esophageal-specific criteria, trastuzumab/T-DXd binding studies, and HER2 heterogeneity assessment — a common challenge in esophageal HER2 testing that impacts therapeutic response.
→ Browse HER2 antibodies & proteins

p53 (TP53) — TP53 mutations are the most frequent genomic alterations in both ESCC (>80%) and EAC (~70%). Anti-p53 antibodies detect mutant p53 protein accumulation by IHC, enabling molecular classification and research into p53-mediated cell cycle dysregulation and therapeutic vulnerability studies.
→ Browse p53 antibodies & proteins

References

1. Doki Y, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449-462. DOI

2. Sun J-M, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590). Lancet. 2021;398(10302):759-771. DOI

3. The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-175. DOI

4. Lordick F, et al. Gastric cancer: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(10):1005-1020. DOI

446 product results for "Esophageal Cancer"

Options+
Options
Confirm
  • Product types
    0 selected
    Assay Kit (1)
    Research Biosimiliar (4)
    Antibodies (196)
    Proteins (51)
    Stable Cell Lines (3)
    Research Biosimilar (191)
  • Expression system
    0 selected
    E. coli (28)
    HEK293T (3)
    Mammalian cells (206)
    Insect cells (1)
  • Target
    0 selected
    EGFR/ERBB1 & TGFBR2/TGFR-2 (1)
    CXCL17/DMC/VCC1 (1)
    CD274/PD-L1 & CD152/CTLA4 (1)
    EGFRvIII-specific/EGFR variant III (2)
    CD366/TIM-3 & CD274/PD-L1 (1)
    CD340/ERBB2 (83)
    CD137/4-1BB & CD340/ERBB2 (2)
    CD274/PD-L1 & CD3E (1)
    CD274/PD-L1 & CD279/PD-1 (1)
    CD332/FGFR2 (18)
    CD340/ERBB2 & CD279/PD-1 (1)
    EGFR (1)
    EGFR/ERBB1 & CD16a/FCGR3A (1)
    TRIAP1 (1)
    ERAP1 (1)
    CD340/ERBB2/HER2 (5)
    CD137/4-1BB/TNFRSF9& CD274/PD-L1/B7-H1 (1)
    CD47/MER6 & PDCD1 / PD-1 / CD279 (1)
    FGF2/bFGF & VEGFA (1)
    CD274/PD-L1 & TGFBR2 (1)
    EGFR/ERBB1 & ERBB3/HER3 (1)
    TIGIT & CD274/PD-L1 (1)
    FLT1/VEGFR1 & CD274/PD-L1 (1)
    VEGF-C/VEGF-D (1)
    CD274/PD-L1 & SLT-Ia (1)
    EGFR/ERBB1 (60)
    CD152/CTLA4 & CD274/PD-L1 (1)
    CD19 & PD-L1 & CD3E & CD137 (1)
    PD-1 & CD3E (1)
    HER2 (domain III) (1)
    C3 & C4B & VEGFA (1)
    CD274/PD-L1 & CD47/MER6 (1)
    EGFR & CD3E (1)
    EGFR/ERBB1 & CD3E (2)
    CD274/PD-L1/B7-H1 (5)
    EGFR/ERBB1/HER1 (5)
    ERBIN (2)
    PDGFC (5)
    KRT5 (3)
    FZR1 (1)
    CD274/PD-L1 & VEGFA (1)
    CD47/MER6 & PDCD1 / PD-1 & CD137/4-1BB/TNFRSF9 (1)
    EGFR/ERBB1 & LGR5 (1)
    EGFR/ERBB1/HER1 & CD3E & Albumin/HSA (1)
    CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)
    CD340/ERBB2 & ERBB3/HER3 (1)
    4-1BB & FAP (1)
    CD274/PD-L1 (72)
    EGFR & CD3E & PD-L1 & 4-1BB (1)
    TIGAR (1)
    WRAP53 (1)
    EGFR/ERBB1 & c-Met/HGFR (1)
    ERBB2 / HER2 / CD340 & CD137/4-1BB/TNFRSF9 (1)
    CD28 & EGFR (1)
    CD274/PD-L1 & CD28 & CD152/CTLA4 (1)
    EGFRvIII & CD3E (1)
    CDH1/CDH11 (5)
    CD314/KLRK1/NKG2D & EGFR/ERBB1/HER1 (1)
    CD274/PD-L1 & CD134/OX40 (1)
    VEGFA (1)
    CD324/CDH1 (13)
    CCND1 (1)
    TP53TG5 (1)
    B7-H3 & EGFR (1)
    CD274/PD-L1 & TGFBR2/TGFR-2 (1)
    NOTCH1 (3)
    CD274/PD-L1 & CD28 (1)
    CD340/ERBB2 & CD3 (1)
    CD340/ERBB2 & CD3E (5)
    CD47/MER6 & CD274/PD-L1/B7-H1 (2)
    TP53 (1)
    CLEC14A (2)
    4-1BB & HER2 (1)
    CD340/ERBB2/HER2 & CD3E (1)
    CD137/4-1BB & CD274/PD-L1 (3)
    KRT7 (3)
    RRM2B (1)
    TP53/p53 (12)
    p53 (R175H mutation) pHLA Complex (1)
    PD-L1 & TGF-Beta (1)
    CD279/PD-1 & CD274/PD-L1 (1)
    CD274/PD-L1 & CD137/TNFRSF9 (1)
    EGFR/ERBB1/HER1 & CD3E (1)
    p-TP53 (1)
    MET/HGFR & EGFR/ERBB1 (2)
    CD172a/SIRPA & CD340/ERBB2 (1)
    TP53BP1 (2)
    EGFR/ERBB1 & CD28 (1)
    EGFRvIII (1)
    Fluorescein & CD274/PD-L1 (1)
    EGFR/ERBB1/HER1&c-MET (1)
    CD340/ERBB2/HER2&CD314/KLRK1/NKG2D (1)
    VSIR/VISTA & CD274/PD-L1 (1)
    CD47/MER6 & CD274/PD-L1 (2)
    PDL1 (6)
  • Species
    0 selected
    Mus musculus (Mouse) (10)
    Rattus norvegicus (Rat) (1)
    Felis catus (Cat) (Felis silvestris catus) (3)
    Mouse (14)
    Canis lupus familiaris (Dog) (Canis familiaris) (5)
    Homo sapiens (Human) (29)
    Tupaia chinensis (Chinese tree shrew) (3)
    Human (201)
  • Applications
    0 selected
    in vivo PD-L1 blockade (3)
    Bioactivity: FACS (183)
    IHC (55)
    SDS-PAGE (51)
    in vitro PD-L1 blockade (3)
    Functional assay (190)
    WB (129)
    Immunogen (51)
    IHC-F (3)
    Research in vivo (190)
    Bioactivity testing in progress (36)
    IF (13)
    IP (4)
    FACS (6)
    Blocking (3)
    Functional assay (6)
    SPR (1)
    RIA (1)
    Neutralization (4)
    in vivo blockade (2)
    FuncS (18)
    ELISA (366)
    FCM (103)
  • Reactivity
    0 selected
    Mouse (56)
    Tupaia chinensis (Chinese tree shrew) (1)
    Rat (4)
    Macaca fascicularis (Crab-eating macaque) (Cynomolgus monkey) (1)
    Human (346)
    Feline (1)
  • Host species
    0 selected
    Rat (8)
    Human (215)
    Mouse (99)
    Rabbit (38)
    HEK293T (3)
    Chimeric (9)
    Alpaca (7)
  • Clonality
    0 selected
    Monoclonal (352)
    Polyclonal (31)
  • Conjugate
    0 selected
    PerCP (19)
    PE (19)
    Unconjugated (280)
    FITC (19)
    APC (19)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only